ATYR Similar Chart Price Prediction
The price of ATYR is predicted to go up 13.56%, based on the high correlation periods with LGIH. The similarity of these two price pattern on the periods is 91.58%.
ATYR
LGIH
Up: 13.56%Similarity: 91.58%
ATYR Revenue Forecast
ATYR EPS Forecast
ATYR FAQs
What is ATYR eps forecast for next quarter？
ATYR Analyst's Forecast
Prakhar Agrawal
Cantor Fitzgerald
Buy
2025-01-06
Price Target
n/a
Downside
0%
Cantor Fitzgerald initiated coverage of aTyr Pharma with an Overweight rating. aTyr Pharma's lead drug Efzofitimod is in two trials for interstitial lung diseases, a Phase 3 trial in pulmonary sarcoidosis, inflammatory lung disease, and a Phase 2 trial in Systemic sclerosis-associated interstitial lung disease, the analyst tells investors in a research note. Cantor is positive on Efzofitimod's prospects in pulmonary sarcoidosis and estimates that it can show a 30% relative reduction in daily steroid use in Phase 3 that should lead to blockbuster commercial opportunity in PS. The firm thinks the stock is pricing in just a 10% probability of success for the Phase 3 in PS vs. the firm's assumption of a 60% POS.
